Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin Duong HK; Sekeres MAClin Interv Aging 2009[]; 4 (ä): 197-205As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower toxicity profiles that can be offered to these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody (hP67.6) which is linked to N-acetyl-gamma calicheamicin 1,2-dimethyl hydrazine dichloride. Once the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated.|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Aminoglycosides/administration & dosage/pharmacology/*therapeutic use[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/administration & dosage/pharmacology/*therapeutic use[MESH]|Antigens, CD/drug effects[MESH]|Antigens, Differentiation, Myelomonocytic/drug effects[MESH]|Antineoplastic Agents/administration & dosage/*therapeutic use[MESH]|Gemtuzumab[MESH]|Humans[MESH]|Leukemia, Myeloid, Acute/*drug therapy/epidemiology/physiopathology[MESH]|Middle Aged[MESH]|Sialic Acid Binding Ig-like Lectin 3[MESH]|United States/epidemiology[MESH]|Young Adult[MESH] |
